[Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes].

INTRODUCTION

Thesis is devoted to the optimization of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes by acting on carbohydrate and lipid metabolism as well as providing hepatoprotection.

AIM

Optimization of diagnostics and treatment in patients treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes.

MATERIAL AND METHODS

Examination and treatment of 117 patients with NAFLD and pre-diabetes and type 2 diabetes was performed.

RESULTS

It has been proved that the use of a therapeutic scheme that includes a balanced diet, taking into account the daily requirement in proteins, fats and carbohydrates, daily 30-minute walks at a brisk pace, rosuvastatin 10 mg/d, omega-3 PUFA 1000 mg/d and ursodeoxycholic acid 10 mg/kg/d in patients with NAFLD and pre-diabetes facilitates regression of signs of steatosis. In patients with NAFLD and type 2 diabetes the above mentioned therapeutic scheme including sitagliptin 100 mg/d promotes regression of steatohepatitis in steatosis.

CONCLUSIONS

The prevalence of nonalcoholic steatohepatitis and liver steatosis in patients with pre-diabetes has been studied. It has been proved that patients with NAFLD and pre-diabetes belong to the group with high cardiovascular risk. The features of metabolic disorders in patients with nonalcoholic fatty liver disease and pre-diabetes or type 2 diabetes were researched. Differentiated treatment schemes of nonalcoholic steatosis and steatohepatitis in patients with pre-diabetes and type 2 diabetes have been approved for use.